Role of atrial natriuretic peptide in mineralocorticoid escape phenomenon in patients with primary aldosteronism.
The withdrawal effect of spironolactone treatment on natriuresis was studied in relation to atrial natriuretic peptide (ANP) in five patients with primary aldosteronism due to adenoma. The patients had been treated with spironolactone for 2-3 months before they were admitted. After admission, blood pressure, body weight, and urinary excretion of sodium were measured daily. Venous samples were obtained twice a week for measurements of plasma levels of ANP, plasma renin activity (PRA), and plasma concentrations of aldosterone (PAC), cortisol, and deoxycorticosterone. The study was performed for 7 days during the treatment with spironolactone and for 18 days after stopping the administration. Plasma volume was determined two times, during the control period and on the 13th day after stopping spironolactone. Urinary sodium excretion decreased initially and returned to the control levels successively. Body weight and plasma volume increased, and blood pressure rose steadily. PRA and the plasma concentrations of cortisol and deoxycorticosterone decreased significantly (P less than 0.05); however, high levels of PAC did not alter significantly. Plasma ANP levels increased significantly (P less than 0.05) from 26 +/- 4 pg/ml during the control period to 195 +/- 47 pg/ml on the 13th day after stopping spironolactone. The data of the urinary sodium excretion showed the escape from sodium-retaining effect of aldosterone, and this escape could be explained by the increase in plasma ANP. Furthermore, ANP might contribute to the decrease in cortisol and deoxycorticosterone in plasma because of the direct inhibitory action of ANP on steroidogenesis.
D000328:Adult; D000450:Aldosterone / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood*; D001794:Blood Pressure; D003900:Desoxycorticosterone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D006929:Hyperaldosteronism / Q000188:drug therapy / Q000503:physiopathology*; D008875:Middle Aged; D008901:Mineralocorticoids / Q000097:blood*; D009318:Natriuresis; D011188:Potassium / Q000097:blood; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000008:administration & dosage / Q000627:therapeutic use*
D008901:Mineralocorticoids; D013148:Spironolactone; D003900:Desoxycorticosterone; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D012083:Renin; D011188:Potassium; D006854:Hydrocortisone